ストックスクリーナーアプリを入手
5.22
1.95%
0.10
アフターアワーズ：
5.20
-0.02
-0.38%
前日終値:
$5.12
開ける：
$5.12
24時間の取引高:
526.08K
Relative Volume:
0.79
時価総額：
$672.39M
収益：
$193.01M
当期純損益:
$-12.15M
株価収益率:
-58.00
EPS:
-0.09
ネットキャッシュフロー:
$454.00K
1週間 パフォーマンス:
-0.19%
1か月 パフォーマンス:
-9.06%
6か月 パフォーマンス:
-7.61%
1年 パフォーマンス:
-40.14%
1日の値動き範囲:
$5.12
$5.28
1週間の範囲:
$5.11
$5.42
52週間の値動き範囲:
$4.66
$9.3283
Cytek Biosciences Inc Stock (CTKB) Company Profile
名前
Cytek Biosciences Inc
セクター
電話
(877) 922-9835
住所
47215 LAKEVIEW BOULEVARD, FREMONT
CTKB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
5.22 | 672.39M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
134.95 | 234.06B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.39 | 154.06B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
387.92 | 148.02B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.17 | 115.71B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.76 | 42.91B | 5.72B | 4.17B | 490.10M | 6.97 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | ダウングレード | Goldman | Buy → Sell |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-07-19 | 開始されました | Raymond James | Mkt Perform |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
Cytek Biosciences Inc (CTKB) 最新ニュース
(CTKB) Proactive Strategies - Stock Traders Daily
Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Update - MarketBeat
Cytek Biosciences (CTKB) Projected to Post Quarterly Earnings on Thursday - Defense World
Cytek Biosciences (NASDAQ:CTKB) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Prenetics Global (NASDAQ:PRE) and Cytek Biosciences (NASDAQ:CTKB) Head to Head Analysis - Defense World
Cytek Biosciences to Announce Q4 and Full Year 2024 Financial Results on February 27, 2025 - Nasdaq
Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - GlobeNewswire
Cytek Biosciences Earnings Alert: Key Q4 and Full Year 2024 Results Coming February 27 - StockTitan
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Cytek Biosciences (NASDAQ:CTKB) Sees Unusually-High Trading Volume – Here’s What Happened - Defense World
Keeping an Eye on Cytek BioSciences Inc (CTKB) After Insider Trading Activity - Knox Daily
Cytek Biosciences (NASDAQ:CTKB) Trading Down 4%Should You Sell? - MarketBeat
Cytek Biosciences (NASDAQ:CTKB) Shares Up 5%What's Next? - MarketBeat
Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Strategic Investor Access: Cytek Sets Ambitious 4-Conference Roadshow for Early 2025 - StockTitan
Pacer Advisors Inc. Buys Shares of 30,155 Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Trading Down 4% – Should You Sell? - Armenian Reporter
Market Insights: Cytek BioSciences Inc (CTKB)’s Notable Gain of 4.66, Closing at 5.39 - The Dwinnex
Cytek Biosciences (NASDAQ:CTKB) Stock Rating Lowered by The Goldman Sachs Group - MarketBeat
Cytek Biosciences price target raised to $5.25 from $4.50 at Goldman Sachs - MSN
Cytek Biosciences (NASDAQ:CTKB) Cut to Sell at The Goldman Sachs Group - Defense World
Cytek Biosciences (NASDAQ:CTKB) Shares Down 5.5%What's Next? - MarketBeat
Cytek Biosciences (NASDAQ:CTKB) Shares Gap DownWhat's Next? - MarketBeat
(CTKB) Trading Report - news.stocktradersdaily.com
Cytek cut from buy to sell by Goldman Sachs (CTKB:NASDAQ) - Seeking Alpha
Goldman Sachs cuts Cytek Biosciences stock rating to sell - MSN
Goldman Sachs Downgrades Cytek Biosciences to Sell From Buy, Adjusts Price Target to $4.50 From $7 - Marketscreener.com
Goldman Sachs cuts Cytek Biosciences stock rating to sell By Investing.com - Investing.com UK
Cytek Biosciences, Inc. (NASDAQ:CTKB) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance
Institutional investors may adopt severe steps after Cytek Biosciences, Inc.'s (NASDAQ:CTKB) latest 24% drop adds to a year losses - Simply Wall St
JPMorgan Chase & Co. Lowers Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Preliminary Full Year 2024 Revenue Results AnnouncedOn January 15, 2025, Cytek Biosciences, Inc. released its preliminary unaudited revenue for the fourth quarter and full year that concluded on December 31, 2024. T - Defense World
Cytek Biosciences expects FY24 revenue to be between $200M and $201M - MSN
Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results - GlobeNewswire
Cytek Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024 - Marketscreener.com
Cytek Biosciences shares take a hit after Q4 sales miss estimates By Investing.com - Investing.com South Africa
Cytek Biosciences shares take a hit after Q4 sales miss estimates - Investing.com Canada
Cytek Biosciences reports 4% annual revenue growth By Investing.com - Investing.com Australia
Cytek Biosciences Shares Fall On Low Preliminary 4Q Revenue - MarketWatch
Cytek Biosciences reports 4% annual revenue growth - Investing.com
Cytek Biosciences Projects 4% Revenue Growth to $201M for 2024, Mixed Q4 Performance - StockTitan
GAMMA Investing LLC Acquires 3,635 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Barclays PLC Increases Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - MarketBeat
Cytek Biosciences Inc (CTKB) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
0.57%
大文字化:
|
ボリューム (24 時間):